Participants. Survivors were identified through the Duke Comprehensive Cancer Center (DCCC) Tumor Registry. Eligible participants seen at Duke for treatment or for consultation, were treated with curative intent, and had no evidence of lymphoma at their last visit at Duke. We further limited our cohort to lymphoma patients with a diagnosis of diffuse large B-cell lymphoma as treatment is more standardized, homogenous, and aggressive than for all subtypes of lymphoma taken together. To reduce the chance of questionnaires mailed to survivors who had died, moved, or otherwise lost to follow up, eligible patients were included in this study only if they had been seen within the Duke University Medical system within 1.5 years prior to the chart review.